<DOC>
	<DOCNO>NCT00002572</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Cytotoxic T cell combine interleukin-2 may effective treatment recurrent brain tumor . PURPOSE : Phase I trial study effectiveness cytotoxic T cell interleukin-2 treat adult recurrent brain tumor .</brief_summary>
	<brief_title>Cytotoxic T Cells Interleukin-2 Treating Adult Patients With Recurrent Brain Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxicity allogeneic cytotoxic T lymphocytes ( CTL ) repeatedly instill directly brain treat recurrent primary brain tumor . II . Evaluate response produce allogeneic CTL interleukin-2 . III . Correlate CTL surface phenotype degree patient/donor HLA mismatch response toxicity . OUTLINE : Surgery plus Biological Response Modifier Therapy . Tumor resection ; plus intracavitary cytotoxic T lymphocytes , CTL ; intracavitary Interleukin-2 ( Chiron ) , IL-2 , NSC-373364 . CTL generate vitro mixing irradiated patient lymphocyte ( culture IL-2 Monoclonal Antibody OKT 3 , MOAB OKT 3 , NSC-618843 ) allogeneic lymphocytes culture mixture IL-2 . PROJECTED ACCRUAL : 10 patient treat . If severe toxicity occur first 5 patient , study close .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Kernohan Grade III/IV primary malignant brain tumor fail conventional surgical resection radiotherapy Evidence recurrent tumor gadoliniumenhanced MRI follow completion radiotherapy ( minimum 5,000 cGy adult ) require The following histology eligible : Anaplastic astrocytoma Anaplastic oligodendroglioma Glioblastoma multiforme Mixed anaplastic glioma Surgical resection progress brain tumor feasible No evidence tumor extend across midline one hemisphere No multifocal tumor leptomeningeal spread PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC great 2,000 Platelets great 100,000 Hct least 28 % Hepatic : Bilirubin le 1.5 mg/dl Renal : Creatinine le 1.5 mg/dl Cardiovascular : No major cardiovascular problem Pulmonary : No major pulmonary problem Other : Seronegative HTLV/HIV , syphilis , hepatitis B C No concurrent systemic infection Ability maintain proper nutrition ( orally intravenously ) study period require No pregnant woman PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : More 4 week since systemic chemotherapy ( 6 week since carmustine ) , WBC increase 2 consecutive determination least 3 day apart Endocrine therapy : Not specify Radiotherapy : At least 8 week since radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>